Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 83 entries
Sorted by: Best Match Show Resources per page
New insights into the Shwachman-Diamond Syndrome-related haematological disorder: hyper-activation of mTOR and STAT3 in leukocytes.

Scientific reports

Bezzerri V, Vella A, Calcaterra E, Finotti A, Gasparello J, Gambari R, Assael BM, Cipolli M, Sorio C.
PMID: 27658964
Sci Rep. 2016 Sep 23;6:33165. doi: 10.1038/srep33165.

Shwachman-Diamond syndrome (SDS) is an inherited disease caused by mutations of a gene encoding for SBDS protein. So far little is known about SBDS exact function. SDS patients present several hematological disorders, including neutropenia and myelodysplastic syndrome (MDS), with...

Cite
Bezzerri V, Vella A, Calcaterra E, et al. New insights into the Shwachman-Diamond Syndrome-related haematological disorder: hyper-activation of mTOR and STAT3 in leukocytes. Sci Rep. 2016;6:33165doi: 10.1038/srep33165.
Bezzerri, V., Vella, A., Calcaterra, E., Finotti, A., Gasparello, J., Gambari, R., Assael, B. M., Cipolli, M., & Sorio, C. (2016). New insights into the Shwachman-Diamond Syndrome-related haematological disorder: hyper-activation of mTOR and STAT3 in leukocytes. Scientific reports, 633165. https://doi.org/10.1038/srep33165
Bezzerri, Valentino, et al. "New insights into the Shwachman-Diamond Syndrome-related haematological disorder: hyper-activation of mTOR and STAT3 in leukocytes." Scientific reports vol. 6 (2016): 33165. doi: https://doi.org/10.1038/srep33165
Bezzerri V, Vella A, Calcaterra E, Finotti A, Gasparello J, Gambari R, Assael BM, Cipolli M, Sorio C. New insights into the Shwachman-Diamond Syndrome-related haematological disorder: hyper-activation of mTOR and STAT3 in leukocytes. Sci Rep. 2016 Sep 23;6:33165. doi: 10.1038/srep33165. PMID: 27658964; PMCID: PMC5034238.
Copy Download .nbib Format: NLM
Influence of alkoxy chain envelopes on the interfacial photoinduced processes in tetraarylporphyrin-sensitized solar cells.

Physical chemistry chemical physics : PCCP

Magnano G, Marinotto D, Cipolla MP, Trifiletti V, Listorti A, Mussini PR, Di Carlo G, Tessore F, Manca M, Orbelli Biroli A, Pizzotti M.
PMID: 26987742
Phys Chem Chem Phys. 2016 Apr 14;18(14):9577-85. doi: 10.1039/c6cp00129g. Epub 2016 Mar 18.

The introduction of alkoxy chains in the molecular architecture of meso push-pull porphyrins is of paramount importance aiming at high performing dye-sensitized solar cells (DSSCs) based on these specific sensitizers. Recently, we have demonstrated that the same approach is...

Cite
Magnano G, Marinotto D, Cipolla MP, et al. Influence of alkoxy chain envelopes on the interfacial photoinduced processes in tetraarylporphyrin-sensitized solar cells. Phys Chem Chem Phys. 2016;18(14):9577-85doi: 10.1039/c6cp00129g.
Magnano, G., Marinotto, D., Cipolla, M. P., Trifiletti, V., Listorti, A., Mussini, P. R., Di Carlo, G., Tessore, F., Manca, M., Orbelli Biroli, A., & Pizzotti, M. (2016). Influence of alkoxy chain envelopes on the interfacial photoinduced processes in tetraarylporphyrin-sensitized solar cells. Physical chemistry chemical physics : PCCP, 18(14), 9577-85. https://doi.org/10.1039/c6cp00129g
Magnano, G, et al. "Influence of alkoxy chain envelopes on the interfacial photoinduced processes in tetraarylporphyrin-sensitized solar cells." Physical chemistry chemical physics : PCCP vol. 18,14 (2016): 9577-85. doi: https://doi.org/10.1039/c6cp00129g
Magnano G, Marinotto D, Cipolla MP, Trifiletti V, Listorti A, Mussini PR, Di Carlo G, Tessore F, Manca M, Orbelli Biroli A, Pizzotti M. Influence of alkoxy chain envelopes on the interfacial photoinduced processes in tetraarylporphyrin-sensitized solar cells. Phys Chem Chem Phys. 2016 Apr 14;18(14):9577-85. doi: 10.1039/c6cp00129g. Epub 2016 Mar 18. PMID: 26987742.
Copy Download .nbib Format: NLM
Acute rosiglitazone treatment during reperfusion after hyperglycemic stroke is neuroprotective not vascular protective.

Translational stroke research

Palomares SM, Sweet JG, Cipolla MJ.
PMID: 23125879
Transl Stroke Res. 2012 Sep;3(3):390-6. doi: 10.1007/s12975-012-0190-9. Epub 2012 May 15.

Reperfusion therapy for ischemic stroke can cause secondary brain injury, especially under hyperglycemic (HG) conditions. Here we investigated the effect of acute treatment with rosiglitazone, a peroxisome proliferator-activated receptor-gamma (PPAR-γ) agonist, prior to postischemic reperfusion, on stroke outcome during...

Cite
Palomares SM, Sweet JG, Cipolla MJ. Acute rosiglitazone treatment during reperfusion after hyperglycemic stroke is neuroprotective not vascular protective. Transl Stroke Res. 2012;3(3):390-6doi: 10.1007/s12975-012-0190-9.
Palomares, S. M., Sweet, J. G., & Cipolla, M. J. (2012). Acute rosiglitazone treatment during reperfusion after hyperglycemic stroke is neuroprotective not vascular protective. Translational stroke research, 3(3), 390-6. https://doi.org/10.1007/s12975-012-0190-9
Palomares, Sara Morales, et al. "Acute rosiglitazone treatment during reperfusion after hyperglycemic stroke is neuroprotective not vascular protective." Translational stroke research vol. 3,3 (2012): 390-6. doi: https://doi.org/10.1007/s12975-012-0190-9
Palomares SM, Sweet JG, Cipolla MJ. Acute rosiglitazone treatment during reperfusion after hyperglycemic stroke is neuroprotective not vascular protective. Transl Stroke Res. 2012 Sep;3(3):390-6. doi: 10.1007/s12975-012-0190-9. Epub 2012 May 15. PMID: 23125879; PMCID: PMC3484888.
Copy Download .nbib Format: NLM
A Case Review Series of Christiana Care Health System's Experience with Negative Pressure Wound Therapy Instillation.

Cureus

Felte R, Gallagher KE, Tinkoff GH, Cipolle M.
PMID: 27980886
Cureus. 2016 Nov 07;8(11):e865. doi: 10.7759/cureus.865.

Acute and chronic wounds afflict a multitude of patients to varying degrees. Wound care treatment modalities span the spectrum of technological advancement and with that differ greatly in cost. Negative pressure wound therapy (NPWT) can now be combined with...

Cite
Felte R, Gallagher KE, Tinkoff GH, et al. A Case Review Series of Christiana Care Health System's Experience with Negative Pressure Wound Therapy Instillation. Cureus. 2016;8(11):e865doi: 10.7759/cureus.865.
Felte, R., Gallagher, K. E., Tinkoff, G. H., & Cipolle, M. (2016). A Case Review Series of Christiana Care Health System's Experience with Negative Pressure Wound Therapy Instillation. Cureus, 8(11), e865. https://doi.org/10.7759/cureus.865
Felte, Robert, et al. "A Case Review Series of Christiana Care Health System's Experience with Negative Pressure Wound Therapy Instillation." Cureus vol. 8,11 (2016): e865. doi: https://doi.org/10.7759/cureus.865
Felte R, Gallagher KE, Tinkoff GH, Cipolle M. A Case Review Series of Christiana Care Health System's Experience with Negative Pressure Wound Therapy Instillation. Cureus. 2016 Nov 07;8(11):e865. doi: 10.7759/cureus.865. PMID: 27980886; PMCID: PMC5144929.
Copy Download .nbib Format: NLM
Improving Tracheostomy Decannulation Rate In Trauma Patients.

Critical care explorations

Farrell MS, Gillin TM, Emberger JS, Getchell J, Caplan RJ, Cipolle MD, Bradley KM.
PMID: 31984377
Crit Care Explor. 2019 Jul;1(7). doi: 10.1097/CCE.0000000000000022.

OBJECTIVE: Identify the effect of a multidisciplinary tracheostomy decannulation protocol (TDP) in the trauma population.DESIGN: Single center retrospective review.SETTING: American College of Surgeons Level 1 Trauma Center; large academic associated community hospital.PATIENTS: Adult trauma patients who required a tracheostomy.INTERVENTIONS:...

Cite
Farrell MS, Gillin TM, Emberger JS, et al. Improving Tracheostomy Decannulation Rate In Trauma Patients. Crit Care Explor. 2019;1(7)doi: 10.1097/CCE.0000000000000022.
Farrell, M. S., Gillin, T. M., Emberger, J. S., Getchell, J., Caplan, R. J., Cipolle, M. D., & Bradley, K. M. (2019). Improving Tracheostomy Decannulation Rate In Trauma Patients. Critical care explorations, 1(7), . https://doi.org/10.1097/CCE.0000000000000022
Farrell, Michael S, et al. "Improving Tracheostomy Decannulation Rate In Trauma Patients." Critical care explorations vol. 1,7 (2019). doi: https://doi.org/10.1097/CCE.0000000000000022
Farrell MS, Gillin TM, Emberger JS, Getchell J, Caplan RJ, Cipolle MD, Bradley KM. Improving Tracheostomy Decannulation Rate In Trauma Patients. Crit Care Explor. 2019 Jul;1(7). doi: 10.1097/CCE.0000000000000022. PMID: 31984377; PMCID: PMC6980485.
Copy Download .nbib Format: NLM
Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination.

Nature

Cho A, Muecksch F, Schaefer-Babajew D, Wang Z, Finkin S, Gaebler C, Ramos V, Cipolla M, Mendoza P, Agudelo M, Bednarski E, DaSilva J, Shimeliovich I, Dizon J, Daga M, Millard KG, Turroja M, Schmidt F, Zhang F, Tanfous TB, Jankovic M, Oliveria TY, Gazumyan A, Caskey M, Bieniasz PD, Hatziioannou T, Nussenzweig MC.
PMID: 34619745
Nature. 2021 Dec;600(7889):517-522. doi: 10.1038/s41586-021-04060-7. Epub 2021 Oct 07.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection produces B cell responses that continue to evolve for at least a year. During that time, memory B cells express increasingly broad and potent antibodies that are resistant to mutations found...

Cite
Cho A, Muecksch F, Schaefer-Babajew D, et al. Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination. Nature. 2021;600(7889):517-522doi: 10.1038/s41586-021-04060-7.
Cho, A., Muecksch, F., Schaefer-Babajew, D., Wang, Z., Finkin, S., Gaebler, C., Ramos, V., Cipolla, M., Mendoza, P., Agudelo, M., Bednarski, E., DaSilva, J., Shimeliovich, I., Dizon, J., Daga, M., Millard, K. G., Turroja, M., Schmidt, F., Zhang, F., Tanfous, T. B., Jankovic, M., Oliveria, T. Y., Gazumyan, A., Caskey, M., Bieniasz, P. D., Hatziioannou, T., & Nussenzweig, M. C. (2021). Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination. Nature, 600(7889), 517-522. https://doi.org/10.1038/s41586-021-04060-7
Cho, Alice, et al. "Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination." Nature vol. 600,7889 (2021): 517-522. doi: https://doi.org/10.1038/s41586-021-04060-7
Cho A, Muecksch F, Schaefer-Babajew D, Wang Z, Finkin S, Gaebler C, Ramos V, Cipolla M, Mendoza P, Agudelo M, Bednarski E, DaSilva J, Shimeliovich I, Dizon J, Daga M, Millard KG, Turroja M, Schmidt F, Zhang F, Tanfous TB, Jankovic M, Oliveria TY, Gazumyan A, Caskey M, Bieniasz PD, Hatziioannou T, Nussenzweig MC. Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination. Nature. 2021 Dec;600(7889):517-522. doi: 10.1038/s41586-021-04060-7. Epub 2021 Oct 07. PMID: 34619745; PMCID: PMC8674133.
Copy Download .nbib Format: NLM
Robustness of aerosol delivery of amikacin liposome inhalation suspension using the eFlow® Technology.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V

Li Z, Perkins W, Cipolla D.
PMID: 34082122
Eur J Pharm Biopharm. 2021 Sep;166:10-18. doi: 10.1016/j.ejpb.2021.05.021. Epub 2021 Jun 01.

The purpose of these studies was to understand the effect on product performance of batch-to-batch variability in both the amikacin liposome inhalation suspension (ALIS) formulation and its delivery device, the Lamira® nebulizer system, designed and manufactured by PARI (PARI...

Cite
Li Z, Perkins W, Cipolla D. Robustness of aerosol delivery of amikacin liposome inhalation suspension using the eFlow® Technology. Eur J Pharm Biopharm. 2021;166:10-18doi: 10.1016/j.ejpb.2021.05.021.
Li, Z., Perkins, W., & Cipolla, D. (2021). Robustness of aerosol delivery of amikacin liposome inhalation suspension using the eFlow® Technology. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 16610-18. https://doi.org/10.1016/j.ejpb.2021.05.021
Li, Zhili, et al. "Robustness of aerosol delivery of amikacin liposome inhalation suspension using the eFlow® Technology." European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V vol. 166 (2021): 10-18. doi: https://doi.org/10.1016/j.ejpb.2021.05.021
Li Z, Perkins W, Cipolla D. Robustness of aerosol delivery of amikacin liposome inhalation suspension using the eFlow® Technology. Eur J Pharm Biopharm. 2021 Sep;166:10-18. doi: 10.1016/j.ejpb.2021.05.021. Epub 2021 Jun 01. PMID: 34082122.
Copy Download .nbib Format: NLM
Sequential immunization of macaques elicits heterologous neutralizing antibodies targeting the V3-glycan patch of HIV-1 Env.

Science translational medicine

Escolano A, Gristick HB, Gautam R, DeLaitsch AT, Abernathy ME, Yang Z, Wang H, Hoffmann MAG, Nishimura Y, Wang Z, Koranda N, Kakutani LM, Gao H, Gnanapragasam PNP, Raina H, Gazumyan A, Cipolla M, Oliveira TY, Ramos V, Irvine DJ, Silva M, West AP, Keeffe JR, Barnes CO, Seaman MS, Nussenzweig MC, Martin MA, Bjorkman PJ.
PMID: 34818054
Sci Transl Med. 2021 Nov 24;13(621):eabk1533. doi: 10.1126/scitranslmed.abk1533. Epub 2021 Nov 24.

[Figure: see text].

Cite
Escolano A, Gristick HB, Gautam R, et al. Sequential immunization of macaques elicits heterologous neutralizing antibodies targeting the V3-glycan patch of HIV-1 Env. Sci Transl Med. 2021;13(621):eabk1533doi: 10.1126/scitranslmed.abk1533.
Escolano, A., Gristick, H. B., Gautam, R., DeLaitsch, A. T., Abernathy, M. E., Yang, Z., Wang, H., Hoffmann, M. A. G., Nishimura, Y., Wang, Z., Koranda, N., Kakutani, L. M., Gao, H., Gnanapragasam, P. N. P., Raina, H., Gazumyan, A., Cipolla, M., Oliveira, T. Y., Ramos, V., Irvine, D. J., Silva, M., West, A. P., Keeffe, J. R., Barnes, C. O., Seaman, M. S., Nussenzweig, M. C., Martin, M. A., & Bjorkman, P. J. (2021). Sequential immunization of macaques elicits heterologous neutralizing antibodies targeting the V3-glycan patch of HIV-1 Env. Science translational medicine, 13(621), eabk1533. https://doi.org/10.1126/scitranslmed.abk1533
Escolano, Amelia, et al. "Sequential immunization of macaques elicits heterologous neutralizing antibodies targeting the V3-glycan patch of HIV-1 Env." Science translational medicine vol. 13,621 (2021): eabk1533. doi: https://doi.org/10.1126/scitranslmed.abk1533
Escolano A, Gristick HB, Gautam R, DeLaitsch AT, Abernathy ME, Yang Z, Wang H, Hoffmann MAG, Nishimura Y, Wang Z, Koranda N, Kakutani LM, Gao H, Gnanapragasam PNP, Raina H, Gazumyan A, Cipolla M, Oliveira TY, Ramos V, Irvine DJ, Silva M, West AP, Keeffe JR, Barnes CO, Seaman MS, Nussenzweig MC, Martin MA, Bjorkman PJ. Sequential immunization of macaques elicits heterologous neutralizing antibodies targeting the V3-glycan patch of HIV-1 Env. Sci Transl Med. 2021 Nov 24;13(621):eabk1533. doi: 10.1126/scitranslmed.abk1533. Epub 2021 Nov 24. PMID: 34818054.
Copy Download .nbib Format: NLM
Treprostinil palmitil inhibits the hemodynamic and histopathological changes in the pulmonary vasculature and heart in an animal model of pulmonary arterial hypertension.

European journal of pharmacology

Corboz MR, Plaunt AJ, Malinin V, Li Z, Gauani H, Chun D, Cipolla D, Perkins WR, Chapman RW.
PMID: 34508752
Eur J Pharmacol. 2021 Sep 08;174484. doi: 10.1016/j.ejphar.2021.174484. Epub 2021 Sep 08.

Treprostinil palmitil (TP) is a long-acting inhaled pulmonary vasodilator prodrug of treprostinil (TRE). In this study, TP was delivered by inhalation (treprostinil palmitil inhalation suspension, TPIS) in a rat sugen 5416 (Su)/hypoxia (Hx) model of pulmonary arterial hypertension (PAH)...

Cite
Corboz MR, Plaunt AJ, Malinin V, et al. Treprostinil palmitil inhibits the hemodynamic and histopathological changes in the pulmonary vasculature and heart in an animal model of pulmonary arterial hypertension. Eur J Pharmacol. 2021;174484doi: 10.1016/j.ejphar.2021.174484.
Corboz, M. R., Plaunt, A. J., Malinin, V., Li, Z., Gauani, H., Chun, D., Cipolla, D., Perkins, W. R., & Chapman, R. W. (2021). Treprostinil palmitil inhibits the hemodynamic and histopathological changes in the pulmonary vasculature and heart in an animal model of pulmonary arterial hypertension. European journal of pharmacology, 174484. https://doi.org/10.1016/j.ejphar.2021.174484
Corboz, Michel R, et al. "Treprostinil palmitil inhibits the hemodynamic and histopathological changes in the pulmonary vasculature and heart in an animal model of pulmonary arterial hypertension." European journal of pharmacology vol. (2021): 174484. doi: https://doi.org/10.1016/j.ejphar.2021.174484
Corboz MR, Plaunt AJ, Malinin V, Li Z, Gauani H, Chun D, Cipolla D, Perkins WR, Chapman RW. Treprostinil palmitil inhibits the hemodynamic and histopathological changes in the pulmonary vasculature and heart in an animal model of pulmonary arterial hypertension. Eur J Pharmacol. 2021 Sep 08;174484. doi: 10.1016/j.ejphar.2021.174484. Epub 2021 Sep 08. PMID: 34508752.
Copy Download .nbib Format: NLM
Long-term amikacin liposome inhalation suspension in cystic fibrosis patients with chronic P. aeruginosa infection.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Bilton D, Fajac I, Pressler T, Clancy JP, Sands D, Minic P, Cipolli M, Galeva I, Solé A, Quittner AL, Jumadilova Z, Ciesielska M, Konstan MW.
PMID: 34144923
J Cyst Fibros. 2021 Nov;20(6):1010-1017. doi: 10.1016/j.jcf.2021.05.013. Epub 2021 Jun 16.

BACKGROUND: . In CLEAR-108-a phase 3, randomised, open-label study-once-daily amikacin liposome inhalation suspension (ALIS) was noninferior to twice-daily tobramycin inhalation solution (TIS) in improving lung function in patients with cystic fibrosis (CF) and chronic Pseudomonas aeruginosa infection after 3...

Cite
Bilton D, Fajac I, Pressler T, et al. Long-term amikacin liposome inhalation suspension in cystic fibrosis patients with chronic P. aeruginosa infection. J Cyst Fibros. 2021;20(6):1010-1017doi: 10.1016/j.jcf.2021.05.013.
Bilton, D., Fajac, I., Pressler, T., Clancy, J. P., Sands, D., Minic, P., Cipolli, M., Galeva, I., Solé, A., Quittner, A. L., Jumadilova, Z., Ciesielska, M., Konstan, M. W. (2021). Long-term amikacin liposome inhalation suspension in cystic fibrosis patients with chronic P. aeruginosa infection. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 20(6), 1010-1017. https://doi.org/10.1016/j.jcf.2021.05.013
Bilton, Diana, et al. "Long-term amikacin liposome inhalation suspension in cystic fibrosis patients with chronic P. aeruginosa infection." Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society vol. 20,6 (2021): 1010-1017. doi: https://doi.org/10.1016/j.jcf.2021.05.013
Bilton D, Fajac I, Pressler T, Clancy JP, Sands D, Minic P, Cipolli M, Galeva I, Solé A, Quittner AL, Jumadilova Z, Ciesielska M, Konstan MW. Long-term amikacin liposome inhalation suspension in cystic fibrosis patients with chronic P. aeruginosa infection. J Cyst Fibros. 2021 Nov;20(6):1010-1017. doi: 10.1016/j.jcf.2021.05.013. Epub 2021 Jun 16. PMID: 34144923.
Copy Download .nbib Format: NLM
Antibody potency, effector function and combinations in protection from SARS-CoV-2 infection .

bioRxiv : the preprint server for biology

Schäfer A, Muecksch F, Lorenzi JCC, Leist SR, Cipolla M, Bournazos S, Schmidt F, Gazumyan A, Baric RS, Robbiani DF, Hatziioannou T, Ravetch JV, Bieniasz PD, Nussenzweig MC, Sheahan TP.
PMID: 32995782
bioRxiv. 2020 Sep 15; doi: 10.1101/2020.09.15.298067.

SARS-CoV-2, the causative agent of COVID-19, is responsible for over 24 million infections and 800,000 deaths since its emergence in December 2019. There are few therapeutic options and no approved vaccines. Here we examine the properties of highly potent...

Cite
Schäfer A, Muecksch F, Lorenzi JCC, et al. Antibody potency, effector function and combinations in protection from SARS-CoV-2 infection . bioRxiv. 2020;doi: 10.1101/2020.09.15.298067.
Schäfer, A., Muecksch, F., Lorenzi, J. C. C., Leist, S. R., Cipolla, M., Bournazos, S., Schmidt, F., Gazumyan, A., Baric, R. S., Robbiani, D. F., Hatziioannou, T., Ravetch, J. V., Bieniasz, P. D., Nussenzweig, M. C., & Sheahan, T. P. (2020). Antibody potency, effector function and combinations in protection from SARS-CoV-2 infection . bioRxiv : the preprint server for biology, . https://doi.org/10.1101/2020.09.15.298067
Schäfer, Alexandra, et al. "Antibody potency, effector function and combinations in protection from SARS-CoV-2 infection ." bioRxiv : the preprint server for biology vol. (2020). doi: https://doi.org/10.1101/2020.09.15.298067
Schäfer A, Muecksch F, Lorenzi JCC, Leist SR, Cipolla M, Bournazos S, Schmidt F, Gazumyan A, Baric RS, Robbiani DF, Hatziioannou T, Ravetch JV, Bieniasz PD, Nussenzweig MC, Sheahan TP. Antibody potency, effector function and combinations in protection from SARS-CoV-2 infection . bioRxiv. 2020 Sep 15; doi: 10.1101/2020.09.15.298067. PMID: 32995782; PMCID: PMC7523108.
Copy Download .nbib Format: NLM
Endoscopic Surgical Excision of Ectopic Tooth in Left Nasal Cavity.

Cureus

Gupta S, Cipolla M.
PMID: 34603864
Cureus. 2021 Aug 26;13(8):e17465. doi: 10.7759/cureus.17465. eCollection 2021 Aug.

Ectopic teeth in the nasal cavity are a rare phenomenon. They are often associated with a variety of symptoms and future complications, ranging from nasal crusting and obstruction to chronic infections. In most reported cases, their removal is recommended....

Cite
Gupta S, Cipolla M. Endoscopic Surgical Excision of Ectopic Tooth in Left Nasal Cavity. Cureus. 2021;13(8):e17465doi: 10.7759/cureus.17465.
Gupta, S., & Cipolla, M. (2021). Endoscopic Surgical Excision of Ectopic Tooth in Left Nasal Cavity. Cureus, 13(8), e17465. https://doi.org/10.7759/cureus.17465
Gupta, Soumya, and Cipolla, Michael. "Endoscopic Surgical Excision of Ectopic Tooth in Left Nasal Cavity." Cureus vol. 13,8 (2021): e17465. doi: https://doi.org/10.7759/cureus.17465
Gupta S, Cipolla M. Endoscopic Surgical Excision of Ectopic Tooth in Left Nasal Cavity. Cureus. 2021 Aug 26;13(8):e17465. doi: 10.7759/cureus.17465. eCollection 2021 Aug. PMID: 34603864; PMCID: PMC8475738.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 83 entries